基于人类蛋白质组芯片的早期鼻咽癌自身抗体发现及生物标记物研究

鼻咽癌作为一种低分化、高转移性恶性肿瘤,在我国南方的发病率位居耳鼻咽喉肿瘤之首。发现可用于鼻咽癌早期筛查、疗效预测和预后判断的低侵袭性特异性生物标记物分子将大大有助于提高鼻咽癌患者的治疗效果和生存率。近几年不断有证据表明自身抗体对于鼻咽癌的检测具有重要价值，但是受分析技术的限制，只发现和研究了少数几种自身抗体。在本项目中，我们将采用核酸可编程蛋白质芯片技术（Nucleic Acid Programmable Protein Arrays，NAPPA)建立首个大规模鼻咽癌的血清自身抗体发现和生物标记物研究技术平台。我们将以早期鼻咽癌肿瘤为研究模式，制备包含有10,000个人源全长蛋白的人类蛋白质组芯片、鉴定鼻咽癌血清自身抗体和研究具有诊断价值的新型自身抗体标记物分子。成功实施该项目可进一步扩展到鼻咽癌肿瘤的迁移、复发和预后等不同阶段，为鼻咽癌的精准诊治研究提供一种有力的蛋白质组学技术手段。

As a poorly differentiated and highly metastatic cancer, nasopharyngeal carcinoma is one of the most malignant tumors in the south of China. Discovery of low-invasive biomarkers that can be used for the early screening, therapeutics and prognosis prediction of nasopharyngeal carcinoma will significantly improve the therapeutic treatment and long survival rate. In previous years, the accumulated evidence indicates that the serological autoantibodies may have great value in nasopharyngeal carcinoma detection. However, due to the limits of analytical technologies, only a few tumor autoantibodies were studied to date. In this project, we will build the first large-scale autoantibody discovery and biomarker study platform for nasopharyngeal carcinoma through a Nucleic Acid Programmable Protein Arrays (NAPPA) technology. With early nasopharyngeal carcinoma as a model, we will fabricate human proteome microarrays containing 10,000 human full-length proteins, screen sera from nasopharyngeal carcinoma patients and identify novel autoantibody biomarkers with diagnostics capability. The successful implementation of this project will be extended to the metastasis, recurrence, prognosis and therapeutic response of nasopharyngeal carcinoma, and provide a proteomics approach for the precision medicine of nasopharyngeal carcinoma.